Research deciphers belapectin’s mechanism of action, further rationalizing its use in combination with checkpoint inhibitors or T cell agonists in oncology and as a monotherapy in NASH cirrhosis ...
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the biotech to advance a program that reportedly attracted the interest of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results